Mediaboss Marketing

The City of West Hollywoods Rent Stabilization Division will host four upcoming virtual trainings for landlords on how to register non-rent-controlled properties and units using the City websites online Landlord Service Portal.

All properties in the City not subject to rent control must be registered, and all new tenancies at those properties must be re-registered within 30 days of the re-rental. Landlords are encouraged to attend one of the following virtual webinars:

These virtual trainings for landlords on registering non-rent-controlled properties and units are free and open to the community. Details and information for each meeting, including Zoom meeting links, is available on the City of West Hollywood website calendar at http://www.weho.org/calendar. Complete information regarding the new registration and re-registration requirements can be found on the Citys website at http://www.weho.org/city-government/rent-stabilization/rental-housing/for-property-owners/non-rso-unit-registry.

Requests for language translation for virtual trainings must be received a minimum of 72 hours before each workshop. For landlords or their representatives who cannot attend a webinar, recorded trainings will be made available on the Citys website for use at any time.

The Citys adoption of Ordinance No. 22-1177 added Section 17.28.050 to the West Hollywood Municipal Code, requiring that, beginning in 2023, most properties with rental units that are not subject to rent control under the Rent Stabilization Ordinance also follow the registration and re-registration process. This includes all multi-family residential rental properties built after July 1, 1979 and any rented condominium or single-family residence.

The online Landlord Service Portal for initial registration of non-rent-controlled properties and units will be available starting Tuesday, April 4, 2023, and landlords must complete the registration process within 30 days of that date. Once a property is registered, the landlord will have an ongoing obligation to re-register new tenancies as they are created.

The City of West Hollywoods Rent Stabilization Division is dedicated to programs that promote the quality of residential life a core value of the City of West Hollywood. The City provides a breadth of information and services to tenants, owners, and property managers of residential rental properties, which includes information services and written materials. For additional information, please visit http://www.weho.org/rsd.

For more information and to RSVP for upcoming virtual trainings for landlords, please contact Roger Vinalon, Jr., City of West Hollywood Administrative Specialist, at rvinalon@weho.org or at (323) 848-6438. For people who are Deaf or hard of hearing, please call TTY (323) 848-6496.

For up-to-date information about City of West Hollywood news and events, follow @wehocity on social media, sign-up for news updates at http://www.weho.org/email, and visit the Citys calendar of meetings and events at http://www.weho.org/calendar. The City of West Hollywood remains in a declared local emergency in response to the coronavirus (COVID-19) pandemic. West Hollywood City Hall is open for walk-in services at public counters or by appointment by visiting http://www.weho.org/appointments. City Hall services are accessible by phone at (323) 848-6400 and via website at http://www.weho.org. The Citys coronavirus updates are available at http://www.weho.org/coronavirus.

For reporters and members of the media seeking additional information about the City of West Hollywood, please contact the City of West Hollywoods Public Information Officer, Sheri A. Lunn, at (323) 848-6391 or slunn@weho.org.

Read more from the original source:
will Host Virtual Workshops on How to Comply with Mandatory ... - City of West Hollywood

Released on March 22, 2023

This year's Agriculture Budget is $548.2 million, a 19 per cent increase from the previous year, with a strong investment in programs, services and agriculture research, as well as a fully-funded suite of business risk management programs.

"Supported by this year's budget, the industry is well-positioned to continue to take on the challenges inherent to agriculture and build on their success," Agriculture Minister David Marit said. "This budget will help Saskatchewan's farmers, ranchers and agri-business remain competitive and operate sustainably while continuing to deliver safe, high-quality food."

The 2023-24 Agriculture Budget contains $89.8 million for strategic initiatives under the federal-provincial Sustainable Canadian Agricultural Partnership, which will launch in the new fiscal year. The budget provides increased support for producers to develop sustainable agriculture water sources like wells, dugouts and pipelines, as well as increased funding for irrigation programming.

The budget includes $1.0 million to target invasive weed control on agricultural Crown land pastures, promoting continued productivity and stewardship of this resource and more than $38 million for agricultural research.

There is $408 million to fund a suite of federal-provincial risk management programs including Crop Insurance and AgriStability. Average Crop Insurance coverage for 2023 is at a record-high level of $446 per acre due to increased commodity prices and yield coverage. The AgriStability compensation rate will increase from 70 to 80 per cent for the 2023 program year, to better support farmers in times of need.

Saskatchewan producers harvested a crop of nearly 35 million tonnes in 2022, with record agri-food exports valued at $18.4 billion.

-30-

For more information, contact:

Continue reading here:
Agriculture Budget Supports Innovative, Sustainable and ... - Government of Saskatchewan

AstraZenecas Calquence (acalabrutinib), a next generation, selective Brutons tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China.

The conditional approval by the National Medical Products Administration (NMPA) was based on positive results from two clinical trials, including the ACE-LY-004 global Phase II trial in adults with relapsed or refractory MCL and a Phase I/ II trial in Chinese patients with relapsed or refractory MCL and other B-cell malignancies.1,2 Continued approval for this indication may be contingent upon verification of ongoing randomised controlled confirmatory trials.

MCL is typically an aggressive, rare form of non-Hodgkin lymphoma (NHL) that accounts for between 2-6% of all patients diagnosed with NHL in China. Patients are generally diagnosed around 60years of age, often at later stages of the disease.3

Jun Zhu, Chief Physician, Department of Lymphatic Oncology, Peking University Cancer Hospital, Beijing, said: Mantle cell lymphomaprogresses rapidly and responds poorly to conventional treatmentsuch as immunochemotherapy.Before the emergence of BTK inhibitors, there were few satisfactory treatment options forpatients.The next-generation BTK inhibitor Calquence has higher target selectivity, fewer side effects, and a higher response rate compared to currently available treatments. This approval of Calquence in China can provide a new treatment option which can better benefit patients with this disease.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: This approval for Calquence offers people living with mantle cell lymphoma in China an effective and tolerable new treatment option to help control their disease. As the first approval in China for Calquence, it is also an exciting step forward for AstraZeneca in blood cancers, enabling us to help more patients across the globe gain access to innovative treatments.

Results from the ACE-LY-004 Phase II trial showed at a median follow up of 15.2 months, investigator-assessed overall response rate (ORR) with Calquence was 80.6% (95% confidence interval [CI] 72.6-87.2), with a complete response (CR) achieved in 39.5% of patients with relapsed or refractory MCL (95% CI 30.9-48.7).1 Longer-term follow-up data showed at 38.1 months, patients treated with Calquence remained progression-free for a median of 22 months, with median overall survival (OS) of 59.2 months (95% CI 36.5-NE).4

Additionally, results from a Phase I/II trial conducted in China showed Calquence achieved a 82.4% ORR, with a CR achieved in 35.3% of patients with MCL based on a blinded independent central-review (BICR) analysis (95% CI 65.5-93.2). Calquence reduced the risk of disease progression or death by 51.5% (95% CI 33.3-67.0) at 12 months, with an estimated duration of response (DOR) of 65.5% (95% CI 66.6-93.3). The median DOR was not reached.2

The safety and tolerability of Calquence in these trials was consistent with that observed in previous clinical trials.1,2,4

Calquenceis approvedfor the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US and Japan and is approved for the treatment of CLL in the EU and in several other countries worldwide in the treatment-nave and relapsed or refractory settings.Calquenceis also approved in the US and several other countries for the treatment of adult patients with MCL who have received at least one prior therapy. Calquenceis not currently approved for the treatment of MCL in Japan or the EU.

Notes

Mantle cell lymphoma (MCL)MCL is a rare B-cell malignancy subtype and is typically clinically aggressive with a poor prognosis.3The epidemiology of MCL in Asia is not well documented, with few published datasets describing the incidence and outcomes.3MCL accounts for between 2-6% of all patients diagnosed with NHL China.3Patients are generally diagnosed around 60years of age and often at later stages of disease (Stage III or IV).3

ACE-LY-004ACE-LY-004 is an open-label, single-arm Phase II clinical trial evaluating Calquence in adult patients with relapsed or refractory MCL.5 Patients in the trial were adults with MCL and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or lower who had relapsed or were refractory to 1-5 prior therapies, had no prior BTK/BCL-2 inhibitor exposure, and did not require warfarin/vitamin K antagonists. Patients received oral Calquence 100mg twice-daily until progressive disease or toxicity. ORR (investigator-assessed partial response or better per Lugano classification), DOR, progression-free survival (PFS), OS and safety were assessed.1

Phase I/II trial in Chinese patientsThe Phase I/II trial is an open-label, multicentre clinical trial evaluatingpharmacokinetics, safety and efficacy ofCalquencein adult Chinese patients with relapsed or refractory MCL and other advanced B-cell malignancies.2In Phase I, patients with relapsed or refractory B-cell malignancies received a single dose ofCalquence100mg orally followed by a two-day washout period and subsequent treatment withCalquence100mg orally twice daily in 28-day cycles, until progressive disease (PD) or treatment discontinuation (TD) for any other reason. In Phase II, patients with relapsed or refractory MCL and ECOG status of 2 or lower receivedCalquence100mg orally twice daily in 28-day cycles until PD or TD. The primary efficacy endpoint was ORR per Lugano classification for NHL assessed by BICR. Secondary endpoints were investigator-assessed ORR, BICR- and investigator-assessed time to response, DOR, PFS, OS and adverse events.2

CalquenceCalquence(acalabrutinib) is a next-generation, selective inhibitor of BTK.Calquencebinds covalently to BTK, thereby inhibiting its activity.6In B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.

Calquenceis approved for the treatment of CLL and SLL in the US, approved for CLL in the EU and many other countries worldwide and approved in Japan for relapsed or refractory CLL and SLL.

As part of an extensive clinical development programme,AstraZeneca is currently evaluating Calquencein more than 20 company-sponsored clinical trials. Calquence is being evaluated for the treatment of multiple B-cell blood cancers, including CLL, MCL, diffuse large B-cell lymphoma, Waldenstrms macroglobulinaemia, marginal zone lymphoma and other haematologic malignancies.

AstraZeneca in haematologyAstraZeneca is pushing the boundaries of science to redefine care in haematology. We have expanded our commitment to patients with haematologic conditions, not only in oncology but also in rare diseases with the acquisition of Alexion, allowing us to reach more patients with high unmet needs. By applying our deep understanding of blood cancers, leveraging our strength in solid tumour oncology and delivering on Alexions pioneering legacy in complement science to provide innovative medicines for rare diseases, we are pursuing the end-to-end development of novel therapies designed to target underlying drivers of disease.

By targeting haematologic conditions with high unmet medical needs, we aim to deliver innovative medicines and approaches to improve patient outcomes. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases, shaped by insights from patients, caregivers and physicians to have the most meaningful impact.

AstraZeneca in oncologyAstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Companys focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visitastrazeneca.comand follow the Company on Twitter@AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Read more:
Calquence granted first regulatory approval in China for adults with ... - AstraZeneca

LOS ANGELES, March 23, 2023 /PRNewswire/ --FaZe Holdings Inc. (Nasdaq: FAZE) ("FaZe Clan"), the lifestyle and media platform rooted in gaming and youth culture, today announced Matt "BK" Augustin has been promoted to Vice President of Brand & Creative Strategy. Augustin, who has been at FaZe Clan for just over two years as Director of Brand & Creative Strategy, will lead a team that will work cross-functionally to optimize FaZe Clan's creative, brand and media strategy. Augustin will report to President and COO, Zach Katz.

"BK is a one-of-a-kind executive and vital asset who not only brings immense value and critical strategy to FaZe Clan, but he also brings steadfast determination and energy that permeates throughout the building everyday," said President and COO Zach Katz. "Lee and I are thrilled to elevate him into a stronger leadership position as we continue to optimize FaZe Clan's creative, brand and media strategy."

As VP of Brand & Creative Strategy, Augustin will oversee a team that's involved in the full life-cycle of business development for FaZe Clan including helping identify existing opportunities for current and potential partners, developing the creative strategy for new business proposals & brand strategy for current and potential partners and working cross-functionally to help produce award-winning content.

"Having a chance to work in gaming, a space that isn't just growing, but one I'm a legit member and contributor of, has been amazing," said Augustin. "Being able to help build a brand like FaZe through the lens of fans first is an opportunity I refuse to take for granted."

During his time at FaZe Clan, Augustin has been instrumental in cementing and continuing partner relationships and collaborations including McDonald's, Porsche, DraftKings, GHOST Energy, MoonPay, SteelSeries, SCUF, DoorDash and Totino's. In 2021, BK was featured on Ad Age's acclaimed 40 Under 40 list recognizing rising stars in marketing, advertising and media.

Prior to joining FaZe, BK worked for multiple reputable advertising agencies including DigitasLBi, FCB Chicago, Fitzco/McCann and 72andSunny where he touched several campaigns with brands including the NFL, Adidas, Under Armour, Activision, and Blizzard Entertainment. In addition to his professional experience, Augustin has dedicated himself to shining a light on the importance of diversity and inclusion by consistently using his presence on LinkedIn to form connections and serve as a mentor for underrepresented professionals. He co-founded the organization Advertising for Change, which focuses on bringing diversity to Atlanta's marketing industry and founded and served as the Global Lead of the McCann World Group Global Diversity Council where he focused on bringing their offices across the world together while pushing for a fair and inclusive environment for all. Bk is also a former ADCOLOR FUTURES board member and current alumni/mentor for Marcus Graham Project.

ABOUT FAZE HOLDINGS INC.FaZe Holdings Inc. (Nasdaq: FAZE) ("FaZe Clan"),is a digital-native lifestyle and media platform rooted in gaming and internet culture, reimagining traditional entertainment for the next generation. Founded in 2010 by a group of kids on the internet, FaZe Clan was created for and by gamers and today operates across multiple verticals with transformative content, tier-one brand partnerships, a collective of notable talent, and fashion and consumer products. Reaching over 500 million followers across social platforms globally, FaZe Clan delivers a wide variety of entertainment spanning video blogs, lifestyle and branded content, gaming highlights and live streams of highly competitive gaming tournaments. FaZe Clan's roster of more than 100 influential personalities consists of engaging content creators, esports professionals, world-class gamers and a mix of talent who go beyond the world of gaming, including NFL star Kyler "FaZe K1" Murray, LeBron "FaZe Bronny" James Jr., Lil Yachty aka "FaZe Boat", Offset aka "FaZe Offset" and Snoop Dogg aka "FaZe Snoop." Its gaming division includes 13 competitive esports teams who have won 37 world championships. The content of any website referenced or hyperlinked in this communication is neither incorporated into, nor part of, this communication. For more information, visit http://www.fazeclan.com, investor.fazeclan.comand follow FaZe Clan on Twitter, Instagram, YouTube, TikTok, and Twitch.

FORWARD LOOKING STATEMENTS:Theinformation in this communication includes "forward-looking statements" pursuant to the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included in this communication, regarding the company's strategy, future operations and financial performance, market opportunity prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words "budget," "could," "forecast," "future," "might," "outlook," "plan," "possible," "potential," "predict," "project," "seem," "seek," "strive," "would," "should," "may," "believe," "intend," "expects," "will," "projected," "continue," "increase," and/or similar expressions that concern strategy, plans or intentions, but the absence of these words does not mean that a statement is not forward-looking. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on the management's belief or interpretation of information currently available.

These forward-looking statements are based on various assumptions, whether or not identified herein, and on the current expectations of management and are not predictions of actual performance. Because forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions, whether or not identified in this communication, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Many factors could cause actual results and condition (financial or otherwise) to differ materially from those indicated in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the company. Forward-looking statements speak only as of the date they are made. While FaZe Clan may elect to update these forward-looking statements at some point in the future, FaZe Clan specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing FaZe Clan's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Press Contacts:FaZe Clan: [emailprotected] + [emailprotected]

SOURCE FaZe Clan

More here:
FAZE CLAN PROMOTES MATT "BK" AUGUSTIN TO VICE ... - PR Newswire

CDC, along with the General Services Administration, today announced the acquisition of a site in Mace, West Virginia for a new facility that will focus on the mining industry and advance the agencys research capabilities. The new National Institute for Occupational Safety and Health (NIOSH) Underground Mine Safety and Health Research Laboratory will support research programs focused on miner safety and health issues.

The mission of the NIOSH Mining Program is to eliminate mining fatalities, injuries, and illnesses through relevant research and impactful solutions, said NIOSH Director John Howard, M.D, M.P.H. The new facility will allow NIOSH to once again conduct full-scale mine explosion studies, support research on various topics such as refuge alternatives and fire suppression and address other issues critical to the safety and health of mine workers.

In March 2023, CDC will begin the planning, design, and construction process for the underground mine safety research facility. CDC anticipates the facility to be completed approximately three years after construction begins.

The acquired site includes approximately 465 acres located off U.S. Route 219 in Randolph and Pocahontas Counties near Mace, West Virginia, and will replace the former Lake Lynn Experimental Mine in Fayette County, Pennsylvania.

NIOSH will now be able to conduct critical research that had to be suspended or redirected after the closing of the Lake Lynn laboratory, said Josh Bornstein, M.P.A., Director of CDCs Office of Safety, Security, and Asset Management. Building this facility supports CDCs master-plan goals to modernize existing laboratory space where economically and programmatically feasible, and to construct new facilities when required.

NIOSH plans, directs, and coordinates a national program to develop and establish recommendations for occupational safety and health standards. NIOSH also conducts research and training, provides technical assistance, and performs related activities to ensure safe and healthful working conditions for every working person in the United States.

For more information about NIOSH please visit NIOSHs website.

Follow this link:
CDC Acquires 465-Acre Site in Mace, West Virginia for Research ... - CDC